Skip to Main Content

Paper Details

Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
J Natl Cancer Inst
4
2022
-related cell types, BRCA1, BRCA2, CNVs, Copy number variants, EOC, EOC-, HGSOC, Noncoding CNVs, ORHGSOC, Ovarian Cancer, PHGSOC, Phigh-grade serous ovarian cancer, RAD51C, RAD51C gene loci, Risk Loci, Single nucleotide polymorphism array, active promoters, epithelial ovarian cancer, insulators, ovarian cancer, ovarian cancer-related cell types, risk alleles, susceptibility regions
Author NameAffiliation
Jonathan TyrerUniversity of Cambridge
Simon G CoetzeeCenter for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center
Katja K H AbenRadboud Institute for Health Sciences, Radboud University Medical Center
Katja K H Aben
Hoda Anton-CulverGenetic Epidemiology Research Institute, University of California Irvine
Hoda Anton-CulverGenetic Epidemiology Research Institute, University of California Irvine
Alicia Beeghly-FadielVanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine
Andrew BerchuckDuke University Hospital
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge
Ian G CampbellPeter MacCallum Cancer Center
Ian G CampbellThe University of Melbourne
Jenny Chang-ClaudeGerman Cancer Research Center (DKFZ)
Jenny Chang-ClaudeUniversity Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute
Anna DeFazioThe Westmead Institute for Medical Research
Anna DeFazioThe University of Sydney
Anna DeFazioWestmead Hospital
Anna DeFazioThe Westmead Institute for Medical Research
Anna DeFazioWestmead Hospital
Anna DeFazioThe University of Sydney
Jennifer A DohertyHuntsman Cancer Institute, University of Utah
Jennifer A DohertyHuntsman Cancer Institute, University of Utah
Peter A FaschingComprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen
Peter A FaschingDavid Geffen School of Medicine, University of California at Los Angeles
Ren??e T FortnerGerman Cancer Research Center (DKFZ)
Graham G Giles
Graham G GilesSchool of Clinical Sciences at Monash Health, Monash University
Graham G GilesThe University of Melbourne
Ellen L GoodeMayo Clinic
Marc T GoodmanSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Jacek GronwaldPomeranian Medical University
Jacek GronwaldPomeranian Medical University
Chad D HuffUniversity of Texas MD Anderson Cancer Center
David G HuntsmanUniversity of British Columbia
David G HuntsmanBC Cancer Research Centre
David G HuntsmanUniversity of British Columbia
David G HuntsmanBC Cancer Research Centre
Beth Y KarlanDavid Geffen School of Medicine, University of California at Los Angeles
Lambertus A KiemeneyRadboud Institute for Health Sciences, Radboud University Medical Center
Diether LambrechtsVIB Center for Cancer Biology
Diether Lambrechts
Usha MenonMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London
Usha MenonMRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London
Roger L Milne
Roger L MilneSchool of Clinical Sciences at Monash Health, Monash University
Roger L MilneThe University of Melbourne
Alvaro N A MonteiroMoffitt Cancer Center
Celeste Leigh PearceUniversity of Michigan School of Public Health ann arbor
Celeste Leigh PearceKeck School of Medicine, University of Southern California Norris Comprehensive Cancer Center
  • 1 - 50

Datasets